AZENTA (AZTA)

Friday

11:00 AM

Thesis: Recent partnerships and product launches are expected to drive revenue growth and enhance market position, shifting investor sentiment positively.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$594M	$615M	$642M
Rev. Growth	+3.6%	+3.6%	+4.4%
EPS	$-1.22	$0.38	$0.59
EPS Growth	+60.5%	+131%	+55.3%
P/E (fwd)	—	96.1×	61.9×

★ Analysts see FY2027 revenue reaching $642M — +4.4% growth in a single year.

What’s Driving the Stock

1Azenta's recent partnership with a leading biopharmaceutical company to integrate its sample management solutions into their R&D processes could drive a 20% increase in new contracts over the next year.
2The launch of a new automated platform that reduces sample processing time by 30% is expected to enhance customer retention and attract new clients.
3Increased funding for biopharmaceutical research due to recent government initiatives could lead to a 15% YoY increase in demand for Azenta's products.
4Increased automation in laboratory processes
5Growth in biopharmaceutical research funding
6Adoption rates of automated sample management systems in biopharmaceutical labs
7Growth in life sciences research funding and expenditure
8Technological advancements in sample management solutions

FY2025 Snapshot

Revenue: $594M
Rev. Growth: +3.6%
Gross Margin: 45.5%
Op. Margin: -1.9%
Net Margin: -9.4%
Net Income: $-56M
NI Growth: +66.2%
EPS: $-1.22
1Y Return: +20.5%

AZTA Chart

My Notes

"Management highlighted, 'Our new partnerships and innovations position us well to capture growing demand in the life sciences sector.'"
Moat: Azenta's proprietary technology and established customer relationships provide a moderate level of competitive advantage.
growth - Investors are likely attracted by the company's potential for revenue growth in the expanding life sciences market.
Interest rates affect Azenta's valuation multiples and financing costs, particularly if the company seeks to expand its operations or invest…
Watch on earnings: Revenue growth rate, Gross margin percentage, Operating cash flow.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $615M to $642M as azenta's recent partnership with a leading biopharmaceutical company to integrate its sample management solutions.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance